Andrew Huberman
Stanford neuroscientist; Huberman Lab podcast
Andrew Huberman is a Stanford neuroscientist whose Huberman Lab podcast is one of the most influential science-communication platforms in health. His April 2024 episode on peptide therapeutics is among the most-cited mainstream explainers on the topic. Huberman takes a deliberately cautious position: he has acknowledged personally trying BPC-157 for a joint issue, but repeatedly stresses that the human evidence is thin and that the real risks — notably BPC-157's promotion of blood-vessel growth (VEGF) and the theoretical tumor concern — are too often glossed over. This page documents his on-record analysis.
Benefits & Risks of Peptide Therapeutics for Physical & Mental Health
There are many animal studies showing efficacy but essentially no clinical trials and few human studies. The 'anecdata' circulating are enticing BUT there are real risks.
Has tried it for joint pain, but flags the VEGF/angiogenesis tumor-risk concern and the absence of human trials.
Treats a narrow subset as legitimate while warning that most circulating uses rest on 'anecdata,' not clinical data.